View : 437 Download: 0

Efficacy of levofloxacin-based third-line therapy for the eradication of helicobacter pylori in peptic ulcer disease

Title
Efficacy of levofloxacin-based third-line therapy for the eradication of helicobacter pylori in peptic ulcer disease
Authors
Lim J.H.Kim S.G.Song J.H.Hwang J.J.Lee D.H.Han J.P.Hong S.J.Kim J.H.Jeon S.W.Kim G.H.Shim K.-N.Shin W.G.Kim T.H.Kim S.M.Chung I.-K.Kim H.-S.Kim H.U.Lee J.Kim J.G.
Ewha Authors
심기남
SCOPUS Author ID
심기남scopus
Issue Date
2017
Journal Title
Gut and Liver
ISSN
1976-2283JCR Link
Citation
Gut and Liver vol. 11, no. 2, pp. 226 - 231
Keywords
Helicobacter pyloriLevofloxacinThird-line eradication
Publisher
Joe Bok Chung
Indexed
SCIE; SCOPUS; KCI WOS scopus
Document Type
Article
Abstract
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease. Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed. Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a protonpump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/ gastroduodenal ulcer, 68.8%, p=0.655). Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
DOI
10.5009/gnl16099
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE